Atrial Fibrillation Post Coronary Artery Graft Surgery: A Review Of Literature

This article was published in the following Dove Press journal:
International Journal of General Medicine

Mansour Jannati
Cardiovascular Surgery Ward, Shiraz University of Medical Sciences, Shiraz, Iran

Abstract: Atrial fibrillation (AF) is a failure that is observed in heart disease and is also known to be the most common heart rhythm disturbance post coronary artery bypass surgery. Although AF is considered a transient problem, it is usually accompanied with a variety of complications and morbidity for patients and may result in death. In the present study, pre- and post-operative considerable factors which may increase the risk and mortality of AF, and possible treatments have been concisely reviewed.

Keywords: atrial fibrillation, cardiac surgery, mortality, risk factor, prophylaxis

Introduction
Atrial fibrillation (AF) is a failure that is observed in heart diseases such as rheumatic and ischemic, as well as thyrotoxicosis and hypertension, and it is also known to be the most common heart rhythm disturbance post coronary artery bypass surgery (CABS). The incidence probability of AF is controversial; for example, of 700 000 patients who undergo open cardiac surgery in the US annually, 11%–40% have AF. Also, based on the results obtained with continuous electrocardiographic monitoring, the incidence range of postoperative AF has been reported to be 25%–40%, and up to 62% after a coronary artery bypass surgery or combined coronary artery bypass surgery and valve procedure. On the other hand, according to the report of the Cleveland Clinic Foundation the prevalence of preoperative electrocardiogram AF incidence was very low (0.96%). Nonetheless, AF still exists and its incidence has not decreased, in spite of the advancement of surgery, anesthesia and care methods post surgery.

Although AF is often benign and transient, various factors, including prolonged length of stay, intensive care unit readmission, a greater need for reintubation, persistent congestive heart failure, stroke, and increased overall costs, have been recognized as associated with postoperative AF. Typical conditions associated with the serious complications of AF include hemodynamic disorders, hypotension caused by the rapid ventricular response, myocardial infarction, cerebral apoplexy, increased length of hospitalization, and death.

The etiology of AF does not indicate a specific factor and there are a number of factors which might lead to the incidence of AF. Potential factors that have been shown to play a role in the creation of atrial susceptibility to AF include: pericarditis, atrial injury from surgical handling or cannulation, atrial suture lines, acute atrial enlargement from pressure or volume overload, inadequate myocardial protection during cardiopulmonary bypass, atrial ischemia, long bypass and aortic...
cross-clamp times, hyperadrenergic states (such as the use of postoperative inotropic medications), pulmonary complications, hypoxemia, inflammation, hypokalemia, and hypomagnesemia.\textsuperscript{23–25}

Since the rate of AF incidence is considerably high and it could come with morbidities that annoy patients, it is a hot point of research in the field of cardiac science. Hence, in the present study we review some aspects of AF disorder after cardiac bypass surgery, including potential pre- and post-operative factors that might play a role in AF incidence, complications that arise with AF, risk of mortality, and management and treatment of AF such as prophylaxis procedures.

**Pre-Operative And Post-Operative Considerations Of AF**

An understanding of the preoperative factors concerned with the incidence of AF would be helpful to minimize morbidities followed by AF, or even to assist prevention. Although some patients develop AF after cardiac surgery without showing any apparent predisposing factors, most patients present at least one clinical predictor. The main preoperative factors which enhance the risk of AF incidence have been summarized in Table 1. These risk factors include increasing age,\textsuperscript{1,28–31} gender,\textsuperscript{32} previous history of AF, increased left atrial size or cardiomegaly, mitral valvular disease (particularly mitral stenosis), previous cardiac surgery, chronic obstructive pulmonary disease (COPD), low-intensity physical activity in the year prior to surgery, elevated preoperative hemoglobin A1c,\textsuperscript{26,33} obesity,\textsuperscript{34,35} and Caucasian race. Other factors which are as significant as the former include absence of beta-blocker or angiotensin converting enzyme inhibitor (ACE inhibitor), preoperative digoxin use,\textsuperscript{36} low-dose dopamine,\textsuperscript{37} higher preoperative plasma concentration of brain natriuretic peptide (BNP),\textsuperscript{1} severe right coronary artery stenosis, preoperative increase in P wave duration on surface (>116 msec)\textsuperscript{38} or on signal-averaged (> 140 msec) ECG.\textsuperscript{29,39}

Also, as potential predicting factors, time of onset (elapsed time), weight gain, fluid distribution, and recovered hematocrit were compared between control and experimental groups.\textsuperscript{32} In terms of elapsed time, it was shown that approximately 70% of patients experienced AF on either the third or fourth postoperative day. In terms of weight gain, 64% of patients gained between 2 and 8 pounds. By looking only at those patients who gained weight and excluding those who remained the same and those who lost weight, the percentage of weight gain rises to 72%. The results of the subject of fluid distribution showed that 66% of patients had a positive fluid balance which means patients gained more fluid than lost it. It might be regarding that 55% of patients with a positive fluid balance had 1000 mL, or more surplus, at the time of atrial arrhythmia. Concerning the hematocrit factor, 76% of patients with AF were able to recover a range of 70–100% of their original erythrocyte count.\textsuperscript{12} Based on these results, excluding weight gain, fluid distribution and hematocrit recovery were similar between the two groups.

**Mortality As A Result Of AF**

Although age is one of the factors that increases the risk of AF incidence and AF seems to be more dominant among older people, using appropriate and applicable statistical methods for studying large population (such as Framingham study) has demonstrated that postoperative AF is associated with reduced survival, independent of age.\textsuperscript{40} AF incidence will be accompanied by morbidity and complications. According to the comparison between AF and non-AF patients, the length of hospital stay was demonstrated to be significantly longer in the AF group. Also, reports indicate a higher rate of early death and stroke in AF patients.\textsuperscript{12}

Retrospective analysis on in-hospital outcomes of AF patients showed that these complications are not just excluded for myocardial infarction, but the probability of occurrence of other complications like stroke, respiratory failure, renal failure, hypotension requiring pressors, multi-system failure, shock, CP arrest, discharge on anticoagulants, and discharge on any antiarrhythmics was significantly higher in AF patients compared to non-AF groups.\textsuperscript{40}

It has been shown that AF is associated with an increased risk of both early and late mortality. Albeit early death in the postoperative period dominates, late mortality is also shown to be statistically significant. This finding was more obvious after exclusion of early mortality cases from

| Preoperative | Postoperative |
|--------------|--------------|
| Increasing age | Weight gain |
| Previous history | |
| Mitral valvular disease | |
| Previous cardiac surgery | |
| Chronic pulmonary disease | |
| Elevated hemoglobin | |
| Low-intensity physical activity | |
| Caucasian | |
| Obesity | |
| Gender | |
the analysis and was even further strengthened by consistent findings in a simultaneous case-matched population. It should be noted that the mechanism of each of short- and long-term mortality as a result of postoperative AF is not similar. In short term mortality, the main AF incidence mechanism is the loss of atrial transport function directly followed by hemodynamic compromise and congestive heart failure (CHF). On the other hand, in the long term mortality, there is no clear mechanistic link and the most probable include adverse drug effect, the occurrence of disabling stroke and embolic catastrophes.41

Management, Prevention, And Treatment

Postoperative AF is usually associated with a higher risk of stroke,42 thus, strategies for preventing stroke should be considered seriously in this setting. Also, clinicians need to pay careful attention to the risk of hemorrhage following surgery, especially when they are going to consider anticoagulation in patients who have not been actively cardioverted. For patients who have been recognized cardioverted within the first 48 h of AF diagnosis with no more recurrence of the arrhythmia, the anticoagulation treatment is not necessary.43

Regarding the high probability of AF after cardiac surgeries, prophylaxis treatment has been strongly recommended especially when there is a risk factor.44 Pieces of evidences have introduced class II β-blockers calcium channel controllers and also amiodarone (an antiarrhythmic drugs agent) as the effective prophylactic drug in controlling and reducing the risk of AF incidence after surgery.5,10 Although several different strategies have been studied to reduce the incidence of AF after cardiac surgery, here, we mainly focus on the role of AADs and B-adrenergic blocking agents (BBs) because they are widely available and have been proven efficient. Overall advantage and disadvantages of amiodarone treatment, as a model of a therapeutic agent, have been presented in Table 2.

| Advantages                                      | Limitations                              |
|------------------------------------------------|------------------------------------------|
| • Diminishing the rate of AF incidence         | • Dominance of other potential diseases  |
| • Shorter hospital stay                        | • Bioavailability and pharmacokinetic matters |
| • Lower hospital cost                          | • Possible side effects                   |
| • Pre-operative consumption                    |                                          |

According to the 2006 American College of Cardiology guidelines, the American Heart Association, and the European Society of Cardiology for the management of AF, BBs was introduced as an impressive agent to prevent postoperative AF.45 The effectiveness of BBs in diminishing the risk of postoperative AF has been supported in a large body of evidence. Atenolol, metoprolol, timolol, propranolol, and carvedilol are among the most studied agents in the postoperative setting and significant differences have been observed in relative efficacy of each of these agents. Based on contemporary practices, BBs can lower the risk of postoperative AF by approximately 30%, which means despite treatment, many patients would still develop AF.42

Among antiarrhythmic agents, amiodarone and sotalol are known to be more safe and efficacious in diminishing the risk of postoperative AF. Sotalol requires daily monitoring during the first five doses. Also, sotalol is dominantly cleared renally, and its use is not feasible in patients with renal dysfunction. In addition, in patients with complications like severe left ventricular dysfunction or congestive heart failure, amiodarone can be the drug of choice.43 Comparative studies between amiodarone and placebo demonstrated that the initial treatment with amiodarone reduced the risk of postoperative AF compare with the placebo group. Also, amiodarone groups showed significantly shorter hospital stays and lower total hospital cost compared to the placebo group.46 In another study, treatment of amiodarone significantly reduced atrial tachyarrhythmias and the risk of sustained ventricular arrhythmias.47 In addition, it has been demonstrated that post-operative prophylaxis with intravenous infusion of amiodarone, followed by oral administration, significantly reduced the incidence of postoperative AF, total costs of care, length of intensive care unit and hospital stay.48,49 Even, oral doses of amiodarone are sufficient to control cardiac arrhythmia.50 It is worth noting that the possible difference in results between therapeutic treatments depends on dosage, duration of treatment, method of consumption (ie, injection, oral), cardiopulmonary bypass, and methods of stopping and continuing β-blocker consumption near surgery.50

However, in spite of the considerable positive outcomes of AADs in patients undergoing cardiac surgery, there are some significant clinical difficulties which limit the use of these agents. It is a fact that patients who undergo cardiac surgery usually have problems such as structural heart disease, coronary artery disease, or impaired left ventricular systolic function. Moreover, there are other factors which...
might impact bioavailability and pharmacokinetics of
ADDs agents in the early postoperative period; factors
such as drug–drug interactions, first-pass metabolism,
alterations in absorption, protein binding, impairment of
elimination pathways and volumes of distribution. For
example, in the case of amiodarone, drug–drug interactions
are a major concern and need more attention to be paid. The
above-mentioned factors contribute to the arrhythmia risk
associated with sodium and potassium channel blockers.43

Also, pre-operative amiodarone prophylaxis has been
shown to be useful to prevent AF occurrence in high-risk
patients.51 Oral consumption of amiodarone for a period of
one week before surgery was stated to reduce AF mani-
festation by 50% and to decrease hospital cost and hospitaliza-
dation duration by 25%.52 On the other hand, consumption of
amiodarone may be accompanied by side effects including
bradycardia, ventricle arrhythmia, cardiac block, interstitial
pneumonia, and liver poisoning. Although the exact
mechanism of the drug effects on AF after surgery is not
clearly known, its effect is postulated to be in relation with
the combination of antiadrenergic and Class I and II antiar-
hythmia drugs.53 Overall effects of prophylactic methods
on the term of hospitalization depend on the balance
between decreasing the AF incidence, and as a result,
decreasing the hospitalization duration on one hand, and
increasing the side effects of the drug on the other hand.50

Conclusion

Atrial fibrillation is a prevalent consequence of coronary
bypass surgery which results in complications and mor-
bidity for patients. Mortality outcome of AF might be
present both long- and short-term, each followed by a
different mechanism. Pre-operative factors such as age,
gender, ethnicity, previous history of AF, and obesity can
increase the risk of AF incidence. Also, post-operative
factors like weight gain might be helpful to predict the
risk of AF occurrence and to provide adequate precautions
and care. Moreover, prophylaxis treatments, especially
with antiarrhythmic drugs (AAD) and B-adrenergic block-
ing agents (BBs), have been shown as the most effective
and available treatments which decrease the risk of AF
incidence as well as length and cost of hospitalization.
Prophylaxis treatments need specific consideration, regard-
ing each agent, and might be accompanied with limitations
and side effects; e.g. sotalol is not recommended for
patients with renal failure and drug–drug interaction is of
concern in the case of amiodarone. Nonetheless, amioda-
one has shown an inhibitory role against AF incidence and
duration of hospitalization, even with oral administration
and before surgery.

Acknowledgment

The author thanks all the participants, especially
Sasan Afifi.

Disclosure

The author reports no conflicts of interest in this work.

References

1. Pires LA, Wagschal AB, Lansey R, Huang SK. Arrhythmias and con-
duction disturbances after coronary artery bypass graft surgery: epide-
niology, management, and prognosis. Am Heart J. 1995;129:799–808.
2. Mendes LA, Connelly GP, McKenney PA, et al. Right coronary
artery stenosis: an independent predictor of atrial fibrillation after
coronary artery bypass surgery. J Am Coll Cardiol. 1995;25:198–
202. doi:10.1016/0735-1097(94)00329-o
3. Crosby LH, Pifalo WB, Woll KR, Burkholder JA. Risk factors for
atrial fibrillation after coronary artery bypass grafting. Am J Cardiol.
1990:66:1520–1522.
4. Lauer MS, Eagle KA, Buckley MJ, DeSanctis RW. Atrial fibrillation
following coronary artery bypass surgery. Prog Cardiovasc Dis.
1989;31:367–378. doi:10.1016/0033-0620(89)90931-5
5. Mason JW. Amiodarone. N Engl J Med. 1987;316:455–466.
doi:10.1056/NEJM198702193160807
6. Faniel R, Schoenfeld P. Efficacy of i.v. amiodarone in converting
rapid atrial fibrillation and flutter to sinus rhythm in intensive care
patients. Eur Heart J. 1983;4:180–185.
7. Cox JL. A perspective of postoperative atrial fibrillation in cardiac
operations. Ann Thorac Surg. 1993;56:405–409. doi:10.1016/0003-
4975(93)90871-e
8. Vecht RJ, Nicolaides EP, Ikweuke JK, Liassides C, Cleary J, Cooper
WB. Incidence and prevention of supraventricular tachyarrhythmias
after coronary bypass surgery. Int J Cardiol. 1986;13:125–134.
doi:10.1016/0167-5273(86)90137-3
9. Quader MA, McCarthy PM, Gillinov AM, et al. Does preoperative
atrial fibrillation reduce survival after coronary artery bypass grafting?
Ann Thorac Surg. 2004;77:1514–1515. discussion 22-4. doi:10.1016/j.athoracsur.2003.09.069
10. Alboni P, Shantha N, Pirani R, et al. Effects of amiodarone on
supraventricular tachycardia involving bypass tracts. Am J Cardiol.
1984;53:93–98. doi:10.1016/0002-9149(84)90690-8
11. Kojuri J, Mahmood Y, Jannati M, Shafa M, Ghazinoor M, Sharifkazemi
MB. Ability of amiodarone and propranolol alone or in combination
to prevent post-coronary bypass atrial fibrillation. Cardiovasc Ther.
2009;27:253–258. doi:10.1111/j.1559-5235.2009.00100.x
12. Tamis JE, Steinberg JS. Atrial fibrillation independently prolongs
hospital stay after coronary artery bypass surgery. Clin Cardiol.
2000;23:155–159. doi:10.1002/clc.4960230305
13. Abreu JE, Reilly J, Salzano RP, Khachane VB, Jekel JF, Clyne CA.
Comparison of frequencies of atrial fibrillation after coronary artery
bypass grafting with and without the use of cardiopulmonary bypass.
Am J Cardiol. 1999;83:775–6,A9. doi:10.1016/S0002-9149(98)00988-6
14. Almassi GH, Schowalter T, Nicolosi AC, et al. Atrial fibrillation after
cardiac surgery: a major morbid event? Ann Surg. 1997;226:501–511.
discussion 11-3. doi:10.1097/00000658-199710000-00011
15. Creswell LL, Schuessler RB, Rosenblum M, Cox JL. Hazards of
postoperative atrial arrhythmias. Ann Thorac Surg. 1993;56:539–549.
doi:10.1016/0003-4975(93)90894-n
16. Weintroub WS, Jones EL, Craver J, Guyton R, Cohen C. Determinants of prolonged length of hospital stay after coronary bypass surgery. *Circulation*. 1989;80:276–284. doi:10.1161/01.cir.80.2.276

17. Galloway AC, Sheinin RJ, Glower DD, et al. First report of the port access international registry. *Ann Thorac Surg*. 1999;67:51–56. discussion 7-8. doi:10.1016/s0003-4975(98)01265-x

18. Dimmer C, Tavernier R, Gjorgov N, Van Nooten G, Clement DL, Jordens L. Variations of autonomic tone preceding onset of arterial fibrillation after coronary artery bypass grafting. *Am J Cardiol*. 1998;82:22–25. doi:10.1016/s0002-9149(98)00231-8

19. Borzak S, Tisdale JE, Amin NB, et al. Atrial fibrillation after bypass surgery: does the arrhythmia or the characteristics of the patients prolong the hospital stay? *Chest*. 1998;113:1489–1491. doi:10.1378/chest.113.6.1489

20. Stafford PJ, Kolvekar S, Cooper J, et al. Signal averaged P wave compared with standard electrocardiography or echocardiography for prediction of atrial fibrillation after coronary bypass grafting. *Heart*. 1997;77:417–422. doi:10.1136/heart.77.5.417

21. Zipes DP. *Braunwald’s Heart Disease: a Textbook of Cardiovascular Medicine*. W.B. Saunders; 2005.

22. Redle JD, Khurana S, Marzan R, et al. Prophylactic oral amiodarone compared with placebo for prevention of atrial fibrillation after coronary artery bypass surgery. *Am Heart J*. 1999;138:144–150. doi:10.1016/s0002-9770(99)70260-7

23. Bramer S, van Straten AH, Soliman Hamad MA, Berreklouw E, Hartogensis OA. The impact of new-onset postoperative atrial fibrillation on mortality after coronary artery bypass grafting. *Ann Thorac Surg*. 2010;90:443–449. doi:10.1016/j.athoracsur.2010.03.083

24. Korantzopoulos P, Kolettis TM, Galaris D, Goudevenos JA. The role of oxidative stress in the pathogenesis and perpetuation of atrial fibrillation. *Int J Cardiol*. 2007;115:135–143. doi:10.1016/j.ijcard.2006.04.026

25. Ehr DA, Parks R, Boisvert D, et al. Preoperative serum potassium levels and perioperative outcomes in cardiac surgery patients. *Multicenter study of perioperative ischemia research group. JAMA*. 1999;281:2203–2210.

26. Zaman AG, Alamgir F, Richens T, Williams R, Rothman MT, Mills NW. Atrial fibrillation after elective coronary artery bypass surgery. *Ann Thorac Surg*. 1998;66:957–961. doi:10.1016/s0002-9149(98)00857-7

27. Argalious M, Motta P, Khandwala F, et al. “Renal dose” dopamine is associated with the risk of new-onset atrial fibrillation after cardiac surgery. *Crit Care Med*. 2005;33:1327–1332. doi:10.1097/01.ccm.0000166876.41694.ca

28. Buxton AE, Josephson ME. The role of P wave duration as a predictor of postoperative atrial arrhythmias. *Chest*. 1981;80:68–73. doi:10.1016/s0003-4975(98)01265-x

29. Steinberg JS, Zelenkofske S, Wong SC, Gelenert M, Sciaccra R, Menchavez E. Value of the P-wave signal-averaged ECG for predicting atrial fibrillation after cardiac surgery. *Circulation*. 1993;88:2618–2622. doi:10.1161/01.cir.88.6.2618

30. Villarreal RP, Hariharan R, Liu BC, et al. Postoperative atrial fibrillation and mortality after coronary artery bypass surgery. *J Am Coll Cardiol*. 2004;43:742–748. doi:10.1016/j.jacc.2003.11.023

31. Loubani M, Hickey MS, Spyt TJ, Galinanes M. Residual atrial fibrillation and clinical consequences following postoperative supraventricular arrhythmias. *Int J Cardiol*. 2000;74:125–132. doi:10.1016/s1277-5273(00)00229-1

32. Burgess DC, Kilborn MJ, Kheech AC. Interventions for prevention of post-operative atrial fibrillation and its complications after cardiac surgery: a meta-analysis. *Eur Heart J*. 2006;27:2846–2857. doi:10.1093/eurheartj/eh272

33. Rho RW. The management of atrial fibrillation after cardiac surgery. *Heart*. 1995;79:422–429. doi:10.1136/hrt.77.7.637

34. Rosenbaum MB, Chiale PA. Control of tachycardia in Wolff-Parkinson-White syndrome by amiodarone hydrochloride. *Am J Cardiol*. 1974;34:215–223. doi:10.1016/0002-9149(74)90200-8

35. European Heart Rhythm A, Heart Rhythm S; Fuster V, Ryden LE, Cannon DS, et al. ACC/AHA/ESC 2006 guidelines for the management of patients with atrial fibrillation-executive summary: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the European Society of Cardiology Committee for Practice Guidelines (Writing Committee to Revise the 2001 Guidelines for the Management of Patients With Atrial Fibrillation). *J Am Coll Cardiol*. 2006;48:854–906.

36. Daud EG, Strickberger SA, Mann KC, et al. Preoperative amiodarone as prophylaxis against atrial fibrillation after heart surgery. *N Engl J Med*. 1997;337:1785–1791. doi:10.1056/NEJM199711233711101

37. Mitchell LB, Exner DV, Wyse DG, et al. Prophylactic oral amiodarone for the prevention of arrhythmias that begin early after revascularization, valve replacement, or repair: PAPABEAR: a randomized controlled trial. *JAMA*. 2005;294:3093–3100. doi:10.1001/jama.294.24.3093

38. Zebris LR, Christensd TD, Kristiansen JS, Hjortdal VE. Amiodarone cost effectiveness in preventing atrial fibrillation after coronary artery bypass graft surgery. *Ann Thorac Surg*. 2008;85:28–32. doi:10.1016/j.jatvs.2007.07.060

39. Zebris LR, Christensd TD, Thomsen HF, et al. Practical regimen for amiodarone use in preventing postoperative atrial fibrillation. *Ann Thorac Surg*. 2007;83:1326–1331. doi:10.1016/j.jatvs.2006.09.096

40. Zebris LR, Christensd TD, Thomsen HF, et al. Practical regimen for amiodarone use in preventing postoperative atrial fibrillation. *Ann Thorac Surg*. 2007;83:1326–1331. doi:10.1016/j.jatvs.2006.09.096
50. Habibollahi P, Jam SH, Vahdati SS, Baghi HM, Amiri H. Amiodaron in atrial fibrillation: post coronary artery bypass graft. *World J Emerg Med*. 2016;7:250–254. doi:10.5847/wjem.j.1920-8642.2016.04.002

51. Budeus M, Hennersdorf M, Perings S, et al. Amiodarone prophylaxis for atrial fibrillation of high-risk patients after coronary bypass grafting: a prospective, double-blinded, placebo-controlled, randomized study. *Eur Heart J*. 2006;27:1584–1591. doi:10.1093/eurheartj/ehi082

52. Hohnloser SH, Meinertz T, Dammbacher T, et al. Electrocardiographic and antiarrhythmic effects of intravenous amiodarone: results of a prospective, placebo-controlled study. *Am Heart J*. 1991;121:89–95. doi:10.1016/0002-8703(91)90960-p

53. Zipes DP, Libby P, Bonow RO, Braunwald E. (2004). Heart Disease: A Textbook of Cardiovascular Medicine. 7th Edition. Philadelphia: Elsevier Science. E. B. Heart Disease. 7th ed. Elsevier 2005.